Fate Therapeutics Inc

FATE06 Dec 2024
Healthcare
$2.55
-0.07 (-7.03%)
Lowest Today
$2.35
Highest Today
$2.62
Today’s Open
$2.55
Prev. Close
$2.56
52 Week High
$8.83
52 Week Low
$1.96
To Invest in Fate Therapeutics Inc

Fate Therapeutics Inc

Healthcare
FATE06 Dec 2024
-0.07 (-7.03%)
1M
3M
6M
1Y
5Y
Low
$2.35
Day’s Range
High
$2.62
2.35
52 Week Low
$1.96
52-Week Range
52 Week High
$8.83
1.96
1 Day
-
1 Week
-25.23%
1 month return
-15.05%
3 month return
-30.29%
6 month return
-37.63%
1 Year return
-1.04%
3 Years return
-95.03%
5 Years return
-82.62%
10 Years return
-
Institutional Holdings
Redmile Group, LLC
11.56
Vanguard Group Inc
9.13
BlackRock Inc
8.88
Deep Track Capital, LP
4.89
State Street Corp
4.61
Boxer Capital LLC
4.36
BB Biotech AG Ord
4.25

Market Status

Fundamentals
Market Cap
291.57 mln
PB Ratio
0.83
PE Ratio
0
Enterprise Value
101.6 mln
Total Assets
506.22 mln
Volume

Company Financials

Fund house & investment objective

Company Information
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
Organisation
Fate Therapeutics Inc
Employees
181
Industry
Biotechnology
CEO
Mr. J. Scott Wolchko
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:

Take your next step